N. P. Christy, M.D.; J. C. Shaver, M.D.; M. S. Roginsky, M.D.
This content is PDF only. Please click on the PDF icon to access.
Two 3-μC doses of 4-C14-estradiol-17 beta were administered intravenously to each of 6 patients with normal hepatic, cardiac, and renal function, 2 patients with viral hepatitis, and 2 patients with Laennec's cirrhosis. Plasma samples were taken at 15, 30, 60, 120, and 240 minutes after injection, extracted with chloroform (85 to 99% recovery of added tritiated estradiol), and assayed for C14 radioactivity in a liquid scintillation counter. Plasma half-times of total administered radioactivity were calculated from the disappearance curves obtained; these showed no significant differences in hepatic disease without ascites (78 to 155 minutes) from normal values (105 to 145
N. P. Christy, J. C. Shaver, M. S. Roginsky. Clearance from Plasma of 4-C14-Estradiol-17 Beta in Patients with Hepatic Disease.. Ann Intern Med. 1963;58:724. doi: 10.7326/0003-4819-58-4-724_1
Download citation file:
Published: Ann Intern Med. 1963;58(4):724.
Gastroenterology/Hepatology, Liver Disease.
Copyright © 2017 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use